Lantheus (LNTH) 46th Annual William Blair Growth Stock Conference summary

Strategic focus on isotopes and radiopharmaceuticals

• Radiopharmaceuticals target specific molecules in the body, enabling precise imaging and therapy, especially for prostate cancer using PSMA-targeted agents.

• Diagnostic agents like PYLARIFY use isotopes such as fluorine-18 to light up tumor cells for PET imaging.

• Therapeutic agents in the pipeline use isotopes like lutetium-177, which can kill cancer cells.

• Isotope selection impacts imaging resolution, scan time, and supply chain logistics due to varying half-lives.

• Supply chain for radiopharmaceuticals is highly time-sensitive, requiring real-time or near real-time production and delivery.

Isotope production and supply chain management

• Fluorine-18 is produced via cyclotrons using oxygen-18 enriched water, while gallium-68 is generated from germanium-68 generators.

• Lutetium-177, used in therapies, is produced in nuclear reactors from ytterbium-176 and has a week-long half-life, allowing global shipment but still requiring rapid administration.

• Supply chain disruptions have occurred due to isotope shortages and manufacturing challenges, but diversification and infrastructure improvements have increased robustness.

• Diagnostic agents benefit from established infrastructure, while new isotopes like copper-64 require new supply chains and investment.

• PET imaging growth is driving investment in cyclotrons, generators, and radiopharmacy capacity.

Imaging infrastructure and workflow optimization

• PET imaging centers are expanding hours and investing in new scanners to meet rising demand.

• F-18 agents allow faster patient throughput compared to gallium-based agents, improving efficiency.

• Staffing and holding room capacity are bottlenecks; industry is working to train more technologists and expand facilities.

• Newer scanners with whole-body imaging and time-of-flight technology reduce scan times and improve image quality.

• Radiation safety protocols vary by isotope half-life, with longer-lived isotopes requiring stricter patient release guidelines.